AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer

 AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer

AstraZeneca Reports Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer

Shots:

  • The P-III CASPIAN study involves assessing of Imfinzi + etoposide with cisplatin/carboplatin CT or Imfinzi + tremelimumab +CT vs CT as monothx. consisting of up to six cycles of CT and optional prophylactic cranial irradiation (PCI) in patients with extensive-stage SCLC in 22+ countries
  •  The P-III CASPIAN study results: median OS (13.0 vs 10.3 mos.); OS rate @18mos. (33.9% vs 24.7%); PFS rate @12 mos. (17.5% vs 4.7%); ORR (67.9% vs 57.6%); DoR @12mos. (22.7% vs 6.3%)
  • Imfinzi is a mAb targeting PD-L1, blocking its interaction with PD-1 and CD80, countering the tumor’s immune-evading tactics and releasing the inhibition of immune responses and is an approved therapy for advanced bladder cancer in 10 countries, including the US

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Coroflot

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post